RESULTS:
After the protocol was put in place, fewer patients required transfusions (38.2% vs. 45.5%, p 5 0.004), with the greatest reduction observed in postoperative blood use (29.1% vs. 37.2%, p 5 0.001). In-hospital morbidity and mortality did not increase. When patients who received transfusions were stratified by procedure, the protocol was most effective in reducing transfusions for patients undergoing isolated coronary artery bypass grafting (CABG; 4.09 units vs. 2.51 units, p 5 0.009) and CABG plus valve surgery (10.32 units vs. 4 .77 units, p 5 0.014). A small group of patients were disproportionate recipients of transfusions, with approximately 6% of all patients receiving approximately half of the blood products. CONCLUSION: A protocol to limit transfusions decreased the proportion of cardiothoracic surgery patients who received blood products. A very small group of patients received a large number of transfusions, and within that group the observed mortality was significantly higher than in the general patient population. Current protocols cannot possibly account for these patients, and this should be considered when analyzing the performance of protocols designed to reduce unnecessary transfusions. C ardiac surgery services use a significant proportion of many hospitals' blood supplies, with 40% to 90% of cases receiving blood products. [1] [2] [3] Blood transfusions provide significant benefits in situations where critically low levels of hemoglobin (Hb) deplete the oxygen supply. 4 The discretionary use of blood products may have negative consequences including altered immune function, pulmonary complications, increased infection rates, longer intensive care unit stay, red blood cell (RBC) alloimmunization, and increased overall mortality, not to mention the potential risks of incompatible transfusions. [5] [6] [7] [8] In addition to the health risks associated with transfusions, blood products are an increasingly expensive component of cardiac surgery. Hospitals in the United States pay approximately $225USD per unit of RBCs, 9 but the administrative and labor costs associated with receipt, storage, transportation, and transfusion of the blood products can more than triple that cost. 10 As such, reducing the unnecessary use of blood products has the potential to control hospital costs associated with blood products and reduce transfusion-related morbidities. Guidelines have broadly recommended transfusing at less than 6 to 7 g/dL Hb and limiting transfusion in patients with Hb level of higher than 10 g/dL and that transfusions should be "considered" for patients with less than 8 g/dL for postoperative surgical patients or patients with cardiovascular disease when symptoms such as chest pain or orthostatic hypotension are present. 11 These guidelines have not been universally adopted, and there is still some controversy in the literature as to the ideal thresholds for transfusion. Cardiac surgery patients who refuse blood transfusions have outcomes similar to those of patients who follow standard care. 12, 13 This combined with increasing evidence of transfusion-related complications in cardiac surgery patients, [5] [6] [7] [8] has sparked interest in more restrictive strategies. 14 To date the evidence is mixed, with no clear indication of whether reducing blood transfusions significantly improves patient outcomes after cardiac surgery. 5, 15 As the debate continues in the literature, clinicians must attempt to balance the potential risks and benefits of transfusion on a day-to-day basis, while hospital administrators monitor ever-increasing costs. The use of a protocol, rather than standalone thresholds for transfusion, may provide a more nuanced guide for the clinical care providers. Although transfusion thresholds help guide decision making, studies have shown that thresholds alone are subject to wide variability in provider compliance. 5 An overall strategy that identifies patients at higher risk of needing transfusion and adapts an institution's standard of care with the goal of reducing the use of blood products may be more effective. The purpose of this study was to determine whether the initiation of a comprehensive blood transfusion protocol could reduce discretionary transfusions and lead to more appropriate use of blood products in a cardiac surgery unit. Our goals were to determine: 1) whether the transfusion protocol successfully reduced unnecessary transfusion in the perioperative and postoperative periods, 2) which operations benefitted most from this change in protocol, and 3) the effects of this change on overall blood product utilization.
MATERIALS AND METHODS

Patient population
This study included all consecutive patients who underwent cardiac surgery at the Valley Hospital between the years of 2010 and 2015, with the protocol initiated on November 1, 2013. A total of 1530 patients were analyzed over a 5-year period, with 736 patients in the pre-transfusion protocol initiation (pre-TPI) period and 794 patients in the post-transfusion protocol initiation (post-TPI) period. Data were prospectively collected using standard elements and definitions from the Society of Thoracic Surgeons (STS) database. The protocol was reviewed by the institutional review board and the need to obtain informed consent was waived for the study. All patient records included in the study were reviewed individually to ensure the quality and accuracy of perioperative transfusion data.
In-hospital protocol
The protocol for the management of perioperative blood transfusions in cardiac patients was developed by a multidisciplinary committee that included cardiothoracic surgeons, intensivists, cardiac anesthesiologists, cardiologists, and perfusionists. The goal of the protocol was to reduce the rates of transfusion, particularly unnecessary transfusions, in cardiac surgery patients (see Supplement S1, available as supporting information in the online version of this paper). The protocol provides guidelines for the identification of individuals who are more likely to need transfusions, suggestions for their perioperative management, intra-and postoperative bloodsparing strategies, and thresholds at which patients should be transfused. The protocol guided but did not dictate clinical practice and emphasized the use of clinical judgment whenever appropriate. Preoperative interventions in patients scheduled for surgery were not universally undertaken during this period and therefore are not reported.
The protocol was implemented in consultation with the hospital blood bank and integrated into the hospital's electronic ordering system to encourage compliance. When orders for blood products were placed via computer, the blood bank would review the orders. If the administration of blood products was not indicated by the protocol, blood bank personnel contacted a member of the transfusion protocol committee, who would advise on whether the order should be filled. If the committee suggested the patient should not be transfused, the ordering physician still had the ability to order blood products based on his or her clinical judgment.
Patient care
Postoperatively, cardiac surgical patients at this center were managed by surgical staff and intensivists in a closed cardiothoracic critical care unit with regular monitoring of Hb and hematocrit (Hct). In the pre-TPI period, the intensive care unit nursing staff could accept physicians' discretionary orders for transfusions. Post-TPI, transfusions ordered contrary to the protocol had to be approved by a member of the protocol committee.
All blood product use, including RBCs, platelets (PLTs), fresh-frozen plasma, and cryoprecipitate, was tracked. As specified by the protocol, RBCs were given when Hct decreased to less than 21% or Hb was measured at less than 7 g/dL. For patients with acute coronary syndromes, this was modified so that Hct less than 24% or Hb less than 8 g/dL was used as the threshold. Patients experiencing ongoing blood loss or acute blood loss that did not respond to appropriate volume were managed with the goal of stabilizing the patient hemodynamically by giving blood transfusions as necessary.
Statistical analysis
Categorical variables are displayed as frequencies with proportions in parentheses and were analyzed using the chi-square test or Fisher's exact test, as appropriate. Continuous data are displayed as means and were analyzed using the unpaired t test, and ordinal data were analyzed with the Mann-Whitney U test. Statistical analyses were performed using computer software (SPSS, Version 19.0, IBM Corp./SPSS).
RESULTS
The patient populations in the pre-TPI and post-TPI periods showed generally similar patterns of demographics, comorbidities, and cardiovascular and surgical risk factors ( Table 1 ). The post-TPI period had a higher proportion of patients with peripheral vascular disease and Class III/IV heart failure and a lower rate of renal failure. Patients presenting in both time periods were similar in urgency of surgery and use of intraaortic balloon support and had similar STS mortality risk scores and risk for reoperation for bleeding. The proportion of isolated valve surgeries was higher and proportion of surgeries categorized as "other" was lower comparing the post-TPI to the pre-TPI period.
Of the 1530 patients, 638 (47.1%) required a blood transfusion during their hospitalization. Use of the blood transfusion protocol reduced the proportion of patients requiring blood products in the post-TPI compared to the pre-TPI time period (38.2% vs. 45.5%, p 5 0.004), with the primary impact of the protocol occurring in the postoperative period (29.1% vs. 37.2%, p 5 0.001; Table 2 ). There were no significant differences in the use of PLTs, plasma, or cryoprecipitate between the pre-and post-TPI periods. The protocol did not have an effect on intraoperative use of blood products between the pre-TPI and post-TPI periods ( Table 2 ). The pattern of blood utilization varied between time periods (Table 3 , Fig. 1 ). There was a strong positive skew to the frequency distributions of transfusions. A majority of patients in both pre-and post-TPI periods received no blood transfusions, and a small group of patients received large amounts of blood (Table 3) . Patients who received more than 10 units of blood represented 5.0% of patients in the pre-TPI period and 7.2% in the post-TPI period, but represented 39.4 and 58.6%, respectively, of the total blood products transfused during the study period (Table 3) .
Analysis by type of procedure demonstrated that the protocol was most effective in reducing the number of transfusions for patients undergoing coronary artery bypass grafting (CABG) and CABG plus valve surgeries (Table 4 ). In the case of CABG plus valve surgeries, the protocol reduced the mean number of units of blood patients received by more than 50%.
There was no increase in mortality or other adverse clinical outcomes after the implementation of the bloodsparing protocol (Table 5 ). In the post-TPI period, there was a significantly lower rate of permanent stroke (0.0% vs. 2.3%, p < 0.0001) and postoperative atrial fibrillation (19.6% vs. 24.0%, p 5 0.037). Patients who received more than 10 blood transfusions had significantly higher rates of mortality in both the pre-and post-TPI period (26.2 and 21.7%, respectively).
In a post hoc analysis of patients who received at least five blood transfusions (Table 6 ), we noted that these patients had a trend toward higher mean age and higher STS predicted risk of mortality. They were more likely to undergo operations in the "other" category, which is a procedure category that included aortic surgeries. With respect to outcomes, almost half of these patients had prolonged ventilation, and almost one-fifth had reoperation for bleeding.
DISCUSSION
The implementation of a protocol to limit unnecessary transfusions was associated with an overall decrease in transfusions in cardiac surgery patients, as well as a shift in the overall pattern of blood utilization. Our results are in line with others in the literature, demonstrating that the implementation of a protocol to reduce transfusions can limit the use of blood products and, specifically in our case, increase the percentage of people who do not receive transfusions, without a significant increase in morbidity or mortality. The decreased incidence of postoperative atrial fibrillation observed after TPI implementation is consistent with some published accounts associated blood transfusions and the risk of atrial fibrillation after surgery. 16 We do not, however, have an explanation for the decreased risk of stroke seen after the protocol was put in place. When analyzed by procedure, there was a significant reduction in the mean amount of blood transfused in patients undergoing coronary revascularization, either alone or in conjunction with a valve intervention. The decrease was particularly notable in the CABG plus valve patients, in whom a 50% reduction was observed. There was no significant change in the mean volume of transfusions for patients undergoing other types of surgery, including isolated valve surgery or non-CABG, nonvalve procedures. This may indicate that revascularization surgeries are particularly amenable to transfusion reduction strategies, but the relatively small number of patients in this single-center study would suggest that further study in a larger, multicenter trial is warranted.
Our analysis identified a small group of patients who were disproportionately high users of blood products.
These "super users" are patients in whom the sheer number of transfusions is indicative of an anticipated, or in some cases unanticipated, catastrophic perioperative course. In our study, the super users had a mean STSpredicted risk that was significantly higher than the overall patient population, and a higher proportion of these patients were undergoing other surgeries, a procedural group that includes higher-risk aortic procedures. This suggests that there was at least some indication before surgery that these were higher-risk patients that may be at greater risk for complications, which were observed in the comparatively high rates of reoperation for bleeding and prolonged ventilation. Transfusion restrictions are unlikely to significantly impact these patients, as they are often transfused in an effort to achieve and maintain some semblance of hemodynamic and clinical stability; these are critically ill patients, and the utility of a transfusion reduction protocol is limited. The phenomenon of super users can be seen clearly in our post-TPI group, where there were more transfusions overall, but also a higher proportion of patients receiving no blood products; there were fewer 1-or 2-unit transfusions, but the super users continued to receive significant amounts of blood products. This was linked to a disproportionally high mortality rate in this subgroup when compared to the rest of the cohort. Super users are likely to have an outsize influence on statistical analyses of blood utilization, and evaluations of transfusion protocols should anticipate and account for these patients in their analyses. This group of individuals also exemplifies the ongoing debate in the literature as to whether blood transfusions are a significant source of morbidity and mortality or whether patients who receive those blood products are at intrinsically higher risk to develop more complications and achieve worse outcomes. We believe that among super users, it is impossible to assign causality to transfusions. The clinical experience in treating cardiac surgery patients who refuse blood products, namely, Jehovah's Witnesses, is perhaps one of the strongest indicators that a restrictive transfusion strategy can be implemented safely. Studies have shown that outcomes among patients who refuse blood products can be similar to low-risk patients who accept blood products when appropriate perioperative measures are taken. 12, [17] [18] [19] Some centers treating Jehovah's
Witness patients have focused exclusively on intraoperative blood saving techniques such as Cell Saver and meticulous closure techniques, 17, 18 while others also include measures such as the use of erythropoietin and iron supplements to treat preoperative anemia and limiting blood collection for routine laboratories. 19 These studies are particularly useful indicators of the ability to safely limit transfusions after cardiac surgery as the Jehovah's Witnesses' strict refusal of any and all blood products prevents the crossover seen in some prospective, randomized trials. While the protocol described in this article constitutes a significant change in the intra-and postoperative management of cardiac patients, no changes were made to preoperative care. Studies have demonstrated that optimization before surgery is particularly important for cardiac surgery patients who refuse blood transfusions, 12, 13 which suggests that such management may also improve patient outcomes under a transfusion reduction protocol. Future studies might consider a variety of preoperative measures to address common issues, such as hypervolemia and preoperative anemia, before cardiac surgery. To improve overall efficacy and, more importantly, patient outcomes, protocols for reducing unnecessary blood transfusions should be integrated into an overall perioperative care plan of evidence-based best practices. Providing feedback to clinicians about their own transfusion practices may increase the efficacy of transfusion reduction protocols. Changing entrenched clinical behaviors is part of an iterative process, and simply implementing a protocol is unlikely to be effective. Beaty and colleagues 20 found that providing feedback improves adherence to blood utilization protocols, particularly when that feedback is provider specific. Studies have reported noncompliance rates as high as 30% to 45%, 5 and this could be another important factor when evaluating the efficacy of transfusion reduction protocols. Our protocol did not include a mechanism for evaluating compliance or providing that information to physicians, which may have improved the overall program effectiveness. Two large prospective, randomized controlled trials of liberal versus restrictive transfusion protocols reported that a restrictive transfusion strategy is comparable to a liberal strategy, conveying no additional risks but also conferring no significant benefits. 5, 15 In the TRACS study, 15 the compliance was significantly better, with only four patients of 502 receiving a transfusion not indicated by the protocol. The TRACS study showed that the restrictive strategy was not inferior to the liberal strategy for transfusion. In the TITRe trial, 5 patients randomly assigned to the liberal transfusion group were transfused immediately after randomization, irrespective of their Hb or Hct, which differs markedly from the standard of care in most major centers. The researchers hypothesized that the restrictive arm would have an event rate of 11% while the liberal strategy would have an event rate of 17%. The actual event rates in the trial were significantly higher, with events occurring at a rate of 35% in the restrictive group and 33% in the liberal group. Clinicians were also able to contravene the assigned threshold provided they documented a rationale, which led to a noncompliance rate of 30.0% in the restrictive group and 45.2% in the liberal group. It is likely that the high rates of both events and noncompliance reflect the discomfort of practitioners with the randomized assignment of their patients and weakens the usefulness of this study in addressing these two approaches.
LIMITATIONS
This study was performed in a single center and its generalizability to other centers may be limited. The design of this study was as a pre-post implementation of the blood transfusion protocol, so patients were not randomly assigned to be treated with or without the protocol, and there may have been other unmeasured differences that could have impacted results when comparing the two periods. As noted, preoperative interventions in patients scheduled for surgery were not universally undertaken during this period and information was not collected for preoperative interventions that could have affected the study results.
CONCLUSION
Our study demonstrated that a protocol for blood transfusion was effective in decreasing the proportion of cardiothoracic surgery patients who received blood products. The impact of the protocol was primarily on blood use in the postoperative period. At our center, the discussion among practitioners regarding weighing the need for transfusion and patient relative risk of complications is active and ongoing. To this end it is vital to maintain flexibility in blood protocol transfusion algorithms such that patients are transfused appropriately. Our experience implementing a transfusion reduction protocol supported the value of a comprehensive and detailed protocol, which resulted in an increase in patients receiving no blood products in the perioperative period. We also identified a small group of patients who use a disproportionately high number of blood products. Transfusion reduction strategies must also take into account the high-risk patients who experience extraordinarily high rates of morbidity and mortality despite receiving large quantities of blood. We strongly suggest that future protocols should not be judged solely by a decrease in overall blood utilization.
